Anne Andermann1, Ingeborg Blancquaert. 1. Family Medicine Centre, St Mary's Hospital, McGill University, 3830 Lacombe Ave, Montreal, QC H3T 1M5. anne.andermann@mcgill.ca
Abstract
OBJECTIVE: To provide a primer for primary care professionals who are increasingly called upon to discuss the growing number of genetic screening services available and to help patients make informed decisions about whether to participate in genetic screening, how to interpret results, and which interventions are most appropriate. QUALITY OF EVIDENCE: As part of a larger research program, a wide literature relating to genetic screening was reviewed. PubMed and Internet searches were conducted using broad search terms. Effort was also made to identify the gray literature. MAIN MESSAGE: Genetic screening is a type of public health program that is systematically offered to a specified population of asymptomatic individuals with the aim of providing those identified as high risk with prevention, early treatment, or reproductive options. Ensuring an added benefit from screening, as compared with standard clinical care, and preventing unintended harms, such as undue anxiety or stigmatization, depends on the design and implementation of screening programs, including the recruitment methods, education and counseling provided, timing of screening, predictive value of tests, interventions available, and presence of oversight mechanisms and safeguards. There is therefore growing apprehension that economic interests might lead to a market-driven approach to introducing and expanding screening before program effectiveness, acceptability, and feasibility have been demonstrated. As with any medical intervention, there is a moral imperative for genetic screening to do more good than harm, not only from the perspective of individuals and families, but also for the target population and society as a whole. CONCLUSION: Primary care professionals have an important role to play in helping their patients navigate the rapidly changing terrain of genetic screening services by informing them about the benefits and risks of new genetic and genomic technologies and empowering them to make more informed choices.
OBJECTIVE: To provide a primer for primary care professionals who are increasingly called upon to discuss the growing number of genetic screening services available and to help patients make informed decisions about whether to participate in genetic screening, how to interpret results, and which interventions are most appropriate. QUALITY OF EVIDENCE: As part of a larger research program, a wide literature relating to genetic screening was reviewed. PubMed and Internet searches were conducted using broad search terms. Effort was also made to identify the gray literature. MAIN MESSAGE: Genetic screening is a type of public health program that is systematically offered to a specified population of asymptomatic individuals with the aim of providing those identified as high risk with prevention, early treatment, or reproductive options. Ensuring an added benefit from screening, as compared with standard clinical care, and preventing unintended harms, such as undue anxiety or stigmatization, depends on the design and implementation of screening programs, including the recruitment methods, education and counseling provided, timing of screening, predictive value of tests, interventions available, and presence of oversight mechanisms and safeguards. There is therefore growing apprehension that economic interests might lead to a market-driven approach to introducing and expanding screening before program effectiveness, acceptability, and feasibility have been demonstrated. As with any medical intervention, there is a moral imperative for genetic screening to do more good than harm, not only from the perspective of individuals and families, but also for the target population and society as a whole. CONCLUSION: Primary care professionals have an important role to play in helping their patients navigate the rapidly changing terrain of genetic screening services by informing them about the benefits and risks of new genetic and genomic technologies and empowering them to make more informed choices.
Authors: Lucie Rychetnik; Penelope Hawe; Elizabeth Waters; Alexandra Barratt; Michael Frommer Journal: J Epidemiol Community Health Date: 2004-07 Impact factor: 3.710
Authors: Robin Z Hayeems; Fiona A Miller; June C Carroll; Julian Little; Judith Allanson; Jessica P Bytautas; Pranesh Chakraborty; Brenda J Wilson Journal: Can Fam Physician Date: 2013-08 Impact factor: 3.275
Authors: Andrea L Shugar; Nada Quercia; Christopher Trevors; Marina M Rabideau; Sohnee Ahmed Journal: J Genet Couns Date: 2016-06-07 Impact factor: 2.537
Authors: John F Thompson; Jeffrey G Reifenberger; Eldar Giladi; Kristen Kerouac; Jaime Gill; Erik Hansen; Avak Kahvejian; Philipp Kapranov; Travis Knope; Doron Lipson; Kathleen E Steinmann; Patrice M Milos Journal: Genome Res Date: 2011-07-15 Impact factor: 9.043